Department of Ophthalmology, University of Wisconsin, Madison, Wisconsin, USA.
Department of Ophthalmology, University of Utah, Salt Lake City, Utah, USA.
Br J Ophthalmol. 2018 Sep;102(9):1268-1276. doi: 10.1136/bjophthalmol-2017-311051. Epub 2018 Jan 11.
Current practice methods are unclear as to the most safe and effective prophylactic pharmacotherapy and method of delivery to reduce postoperative endophthalmitis occurrence.
A systematic review and meta-analysis using Meta-analysis of Observational Studies in Epidemiology guidelines was performed to compare the efficacy of intracameral cefuroxime, moxifloxacin and vancomycin in preventing postphacoemulsification cataract surgery endophthalmitis. A safety analysis of intracameral antibiotics was concurrently performed.
BIOSIS Previews, CINAHL, ClinicalTrials.gov, Cochrane Library, Dissertations & Theses, EMBASE, PubMed, ScienceDirect and Scopus were searched from inception to January 2017. Data were pooled using a random effects model. All articles were individually reviewed and data were extracted by two independent reviewers. Funnel plot, risk of bias and quality of evidence analyses were performed.
Seventeen studies with over 900 000 eyes were included, which favoured the use of intracameral antibiotics at the end of cataract surgery (OR 0.20; 95% CI 0.13 to 0.32; P<0.00001). The average weighted postoperative endophthalmitis incidence rates with intracameral cefuroxime, moxifloxacin and vancomycin were 0.0332%, 0.0153% and 0.0106%, respectively. Secondary analyses showed no difference in efficacy between intracameral plus topical antibiotics versus intracameral alone (P>0.3). Most studies had low to moderate risk of bias. The safety analysis showed minimal toxicity for moxifloxacin. Dosing errors led to the majority of toxicities with cefuroxime. Although rare, vancomycin was associated with toxic retinal events.
Intracameral cefuroxime and moxifloxacin reduced endophthalmitis rates compared with controls with minimal or no toxicity events at standard doses. Additionally, intracameral antibiotics alone may be as effective as intracameral plus topical antibiotics.
目前,对于如何选择最安全、有效的预防性药物治疗以及给药方法来降低白内障术后眼内炎的发生,尚无明确的临床实践方法。
本研究采用观察性研究荟萃分析的系统评价方法,旨在比较玻璃体内注射头孢呋辛、莫西沙星和万古霉素预防白内障超声乳化术后眼内炎的疗效。同时对玻璃体内抗生素的安全性进行了分析。
从建库至 2017 年 1 月,检索 BIOSIS Previews、CINAHL、ClinicalTrials.gov、Cochrane Library、Dissertations & Theses、EMBASE、PubMed、ScienceDirect 和 Scopus 数据库。采用随机效应模型对数据进行合并。所有文章均由两位独立的评审员进行单独评审和数据提取。进行漏斗图分析、偏倚风险评估和证据质量分析。
共纳入 17 项研究,超过 90 万只眼,结果均表明白内障术后应用玻璃体内抗生素可降低眼内炎的发生率(OR 0.20;95%CI 0.13 至 0.32;P<0.00001)。玻璃体内注射头孢呋辛、莫西沙星和万古霉素后平均加权眼内炎发生率分别为 0.0332%、0.0153%和 0.0106%。进一步分析表明,玻璃体内联合局部应用抗生素与单纯玻璃体内应用抗生素的疗效无差异(P>0.3)。大多数研究的偏倚风险为低到中度。安全性分析显示莫西沙星的毒性最小。头孢呋辛的毒性主要与剂量错误有关。万古霉素虽罕见,但与毒性视网膜事件相关。
与对照组相比,玻璃体内注射头孢呋辛和莫西沙星可降低眼内炎发生率,且在标准剂量下,两者的毒性或不良反应发生率低或无。此外,单纯玻璃体内应用抗生素可能与玻璃体内联合局部应用抗生素同样有效。